UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2024
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices; Zip Code)
Registrant’s telephone number, including area code: (617 ) 679-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 1, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the second quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The exhibits listed below are furnished as part of this Current Report on Form 8-K.
| Exhibit No. | Description | ||||
| 99.1 | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIOGEN INC. | |||||
| By: | /s/ Wendell Taylor | ||||
| Wendell Taylor | |||||
| Secretary | |||||
Date: August 1, 2024
Press ReleaseCambridge, Mass. – Aug. 1, 2024
Biogen reports strong second quarter 2024 results and raises full year 2024 financial guidance; Second quarter 2024 total revenue of $2.5 billion, GAAP diluted EPS of $4.00 and Non-GAAP diluted EPS of $5.28
Second quarter total revenue was flat at actual currency and up 1% at constant currency, with GAAP diluted EPS decline of 2% and Non-GAAP diluted EPS increase of 31% year-over-year
•Core pharmaceutical revenue (product revenue + LEQEMBI) up 5% at actual currency and 6% at constant currency year-over-year
•GAAP and Non-GAAP diluted EPS includes $0.52/share benefit from sale of one of Biogen's two priority review vouchers (PRV); net proceeds expected to be reinvested in growth initiatives this year
•GAAP and Non-GAAP operating income grew 34% and 43%, respectively, year-over-year (excluding PRV sale, GAAP and Non-GAAP operating income grew 18% and 30%, respectively)
•Excluding PRV sale, GAAP diluted EPS declined 14% and Non-GAAP diluted EPS up 18% year-over-year
In Alzheimer's disease, LEQEMBI launch delivered accelerated sequential growth with second quarter global in-market sales of approximately $40 million, including U.S. in-market sales of approximately $30 million; Clinical data presented at AAIC demonstrates three years of continuous treatment with dual-acting LEQEMBI continues to benefit early Alzheimer’s disease patients; Eisai to seek CHMP re-examination in the E.U.; Plans to accelerate proof of concept outcome for anti-tau program (BIIB080)
Rare disease franchise further established with SKYCLARYS second quarter global revenue of $100 million, as launches continued to demonstrate global growth potential of the brand; Dose-finding study for pediatric indication underway
ZURZUVAE second quarter revenue of $15 million with launch continuing to show encouraging trends
Biogen completed the acquisition of Human Immunology Biosciences (HI-Bio), expanding its immunology portfolio and bolstering its late-stage pipeline with the addition of three potential phase 3 program starts
Biogen decides to retain Biosimilars business
Increasing full year 2024 financial guidance: Non-GAAP EPS now expected to be between $15.75 and $16.25, representing EPS growth of approximately 9% at the mid-point versus full year 2023
•Now expect total revenue to decline by a low-single digit percentage versus 2023 with core pharmaceutical revenue expected to be roughly flat versus 2023
•Now expect operating income to grow at a mid- to high-teen percentage versus 2023 with expected mid-single digit percentage operating margin improvement
Biogen Inc. (NASDAQ: BIIB) today reported second quarter 2024 financial results. Commenting on the quarter, President and Chief Executive Officer Christopher A. Viehbacher said:
“Biogen delivered strong financial performance in the second quarter thanks to solid execution against our business strategy, which is aimed at transforming the Company to deliver sustainable growth. We saw continued positive momentum across new product launches and are pleased with the trends we see with key products going into the third quarter. We believe we have created a strong mid- to late-stage development pipeline thanks to reprioritization efforts made last year and key acquisitions like HI-Bio,
1
which was announced in the quarter. Our Fit for Growth program announced in early 2023 continues to deliver significant savings, allowing us to strategically reinvest a portion back into product launches and the pipeline."
Financial Highlights
| Q2 '24 | Q2 '23 | △ | r (CC*) | |||||||||||||||||||||||
| Total Revenue (in millions) | $2,465 | $2,456 | 0% | 1% | ||||||||||||||||||||||
| GAAP diluted EPS | $4.00 | $4.07 | (2)% | —% | ||||||||||||||||||||||
| Non-GAAP diluted EPS | $5.28 | $4.02 | 31% | —% | ||||||||||||||||||||||
Note: Percent changes represented as favorable/(unfavorable) versus the prior year period.
* Percentage changes in revenue growth at constant currency (CC) are presented excluding the impact of changes in foreign currency exchange rates and hedging gains or losses. Foreign currency revenue values are converted into U.S. Dollars using the exchange rates from the end of the previous calendar year.
A reconciliation of GAAP to Non-GAAP financial measures can be found in Table 4 at the end of this news release.
Revenue Summary
| (in millions) | Q2 '24 | Q2 '23 | △ | r (CC*) | ||||||||||||||||||||||
Multiple sclerosis (MS) product revenue(1) | $1,150 | $1,209 | (5)% | (5)% | ||||||||||||||||||||||
Rare disease revenue(2) | $534 | $438 | 22% | 25% | ||||||||||||||||||||||
| Biosimilars revenue | $198 | $195 | 2% | 1% | ||||||||||||||||||||||
Other product revenue(3) | $18 | $3 | 431% | 441% | ||||||||||||||||||||||
| Total product revenue | $1,900 | $1,846 | 3% | 4% | ||||||||||||||||||||||
| Revenue from anti-CD20 therapeutic programs | $445 | $433 | 3% | 3% | ||||||||||||||||||||||
| Contract manufacturing, royalty and other revenue | $121 | $177 | (32)% | (32)% | ||||||||||||||||||||||
| Total revenue | $2,465 | $2,456 | 0% | 1% | ||||||||||||||||||||||
Note: Percent changes represented as favorable/(unfavorable) versus the prior year period. Numbers may not foot or recalculate due to rounding.
(1) Multiple sclerosis includes TECFIDERA®, VUMERITY®, AVONEX®, PLEGRIDY®, TYSABRI® and FAMPYRA™.
(2) Rare disease includes SPINRAZA®, SKYCLARYS®and QALSODY®.
(3) Other includes ADUHELM®, FUMADERM™ and ZURZUVAE™.
•Second quarter 2024 ZURZUVAE revenue was approximately $15 million.
Expense Summary
| (in millions) | Q2 '24 | Q2 '23 | △ | |||||||||||||||||
GAAP cost of sales* | $546 | $593 | 8% | |||||||||||||||||
| % of Total Revenue | 22% | 24% | ||||||||||||||||||
Non-GAAP cost of sales* | $504 | $593 | 15% | |||||||||||||||||
| % of Total Revenue | 20% | 24% | ||||||||||||||||||
| GAAP R&D expense | $514 | $584 | 12% | |||||||||||||||||
| Non-GAAP R&D expense | $464 | $584 | 21% | |||||||||||||||||
| GAAP SG&A expense | $554 | $548 | (1)% | |||||||||||||||||
| Non-GAAP SG&A expense | $542 | $534 | (1)% | |||||||||||||||||
Note: Percent changes represented as favorable/(unfavorable) versus the prior year period
* Excluding amortization and impairment of acquired intangible assets
•There were no idle capacity charges in the second quarter of 2024. Second quarter 2023 GAAP and Non-GAAP cost of sales includes approximately $34 million of idle capacity charges. The decrease in second quarter 2024 GAAP and Non-GAAP cost of sales as a percentage of total revenue was driven
2
primarily by product mix, particularly the year-over-year increase in revenue from new product launches and decrease in contract manufacturing revenue, as well as less idle capacity charges.
•In the second quarter 2024 as compared to the second quarter of 2023, the decrease in GAAP and Non-GAAP R&D of approximately $70 million and $120 million, respectively, was primarily due to savings achieved from the Company's R&D portfolio prioritization and Fit for Growth initiatives.
•In the second quarter 2024 as compared to the second quarter of 2023, the increase in GAAP and Non-GAAP SG&A expense of approximately $6 million and $8 million, respectively, was primarily due to increased commercialization spend related to new product launches, partially offset by savings achieved from the Company's Fit for Growth initiative.
Other Financial Highlights
•Second quarter 2024 GAAP and Non-GAAP collaboration profit sharing was a net expense of $62 million, which includes $56 million related to Biogen’s collaboration with Samsung Bioepis, and $6 million to Sage Therapeutics related to the commercialization of ZURZUVAE in the U.S.
•Second quarter 2024 GAAP and Non-GAAP priority review voucher gain on sale, net was approximately $89 million.
•Second quarter 2024 GAAP other expense was $85 million, primarily driven by net interest expense and net unrealized losses on strategic equity investments of $30 million. Second quarter 2024 Non-GAAP other expense was $55 million, primarily driven by net interest expense.
•Second quarter 2024 GAAP and Non-GAAP effective tax rates were 16.5% and 15.9%, respectively. Second quarter 2023 GAAP and Non-GAAP effective tax rates were 16.2% and 15.7%, respectively.
Financial Position
•Second quarter 2024 net cash flow from operations was $626 million. Capital expenditures were $34 million, and free cash flow, defined as net cash flow from operations less capital expenditures, was $592 million.
•As of June 30, 2024, Biogen had cash, cash equivalents, and marketable securities totaling approximately $1.9 billion and approximately $6.3 billion in total debt, resulting in net debt of approximately $4.4 billion. Subsequent to the end of the quarter, Biogen utilized $1.15 billion of cash to acquire HI-Bio, which is not included in these figures.
•As of June 30, 2024, the $1.0 billion 2023 Term Loan which was put in place at the time of the Reata acquisition has been repaid.
•No shares of the Company’s common stock were repurchased in the second quarter of 2024. As of June 30, 2024, there was $2.1 billion remaining under the share repurchase program authorized in October 2020.
•For the second quarter of 2024 the Company’s weighted average diluted shares were 146 million.
3
Full Year 2024 Financial Guidance
For the full year 2024, Biogen now expects a Non-GAAP diluted EPS guidance range as follows:
| Prior FY 2024 Guidance | Updated FY 2024 Guidance | ||||||||||
| Non-GAAP diluted EPS | $15.00 to $16.00 Reflecting growth of ~5% at the mid-point* | $15.75 to $16.25 Reflecting growth of ~9% at the mid-point* | |||||||||
*Versus reported full year 2023
Biogen now expects total revenue to decline by a low-single digit percentage (previously low to mid-single percentage), with core pharmaceutical revenue, defined as product revenue plus Biogen's 50% share of net LEQEMBI product revenue and cost of sales, including royalties, to be relatively flat for 2024 compared to 2023 as further declines in multiple sclerosis product revenue are expected to be offset by increases in revenue from new product launches.
Biogen continues to expect an improvement in the cost of sales as a percentage of total revenue for 2024 compared to 2023 driven by product mix and significantly lower idle capacity charges.
Biogen expects to reinvest the proceeds from the sale of one of the Company's two priority review vouchers in growth initiatives in 2024.
For 2024 compared to 2023, Biogen now expects operating income to grow at a mid- to high-teen percentage with mid-single digit percentage point operating margin improvement. This is expected to be driven by improved cost of sales as a percentage of revenue, as well as lower operating expenses as a result of the Company's Fit for Growth and R&D prioritization programs.
This financial guidance does not include any impact from potential acquisitions or large business development transactions or pending and future litigation, as all are hard to predict, or any impact of potential tax or healthcare reform. Biogen may incur charges, realize gains or losses, or experience other events or circumstances in 2024 that could cause any of these assumptions to change and/or actual results to vary from this financial guidance.
This guidance also assumes that foreign exchange rates as of July 26, 2024, will remain in effect for the remainder of the year, net of hedging activities. Other modeling considerations will be provided on the conference call and webcast.
Biogen does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the Company is unable to predict with reasonable certainty the financial impact of items such as the transaction, integration, and certain other costs related to acquisitions or large business development transactions; unusual gains and losses; potential future asset impairments; gains and losses from our equity security investments; and the ultimate outcome of pending or future significant litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the Company is unable to address the significance of the unavailable information, which could be material to future results.
Key Recent Events
•Today Biogen announced the termination of the Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ) with Denali Therapeutics.
Conference Call and Webcast
4
The Company’s earnings conference call for the second quarter will be broadcast via the internet at 8:30 a.m. ET on August 1, 2024 and will be accessible through the Investors section of Biogen’s website, www.biogen.com. Supplemental information in the form of a slide presentation is also accessible at the same location on the internet and will be subsequently available on the website for at least 90 days.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.
We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
We routinely post information that may be important to investors on our website at
www.biogen.com. Follow us on social media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; the potential benefits, safety, and efficacy of our and our collaboration partners’ products and investigational therapies; the anticipated benefits and potential of investments, optimization of the cost structure including our "Fit for Growth" program, actions to improve risk profile and productivity of R&D pipeline, collaborations, and business development activities; our future financial and operating results; 2024 financial guidance. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management, personnel and other organizational changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media and artificial
5
intelligence based software for our business; results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; risks relating to access to capital and credit markets; risks related to indebtedness; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.
These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
###
| MEDIA CONTACT: | INVESTOR CONTACT: | ||||
| Biogen | Biogen | ||||
| Jack Cox | Chuck Triano | ||||
Tel: +1 781-464-3260 | Tel: +1 781-464-2442 | ||||
public.affairs@biogen.com | IR@biogen.com | ||||
6
TABLE 1
BIOGEN INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(unaudited, in millions, except per share amounts)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||||
| Product, net | $ | 1,899.6 | $ | 1,845.8 | $ | 3,611.5 | $ | 3,609.1 | ||||||||||||||||||
| Revenue from anti-CD20 therapeutic programs | 444.5 | 433.4 | 838.5 | 832.9 | ||||||||||||||||||||||
| Contract manufacturing, royalty and other revenue | 120.8 | 176.8 | 305.4 | 477.0 | ||||||||||||||||||||||
| Total revenue | 2,464.9 | 2,456.0 | 4,755.4 | 4,919.0 | ||||||||||||||||||||||
| Cost and expense: | ||||||||||||||||||||||||||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 546.0 | 592.7 | 1,088.2 | 1,255.5 | ||||||||||||||||||||||
| Research and development | 513.9 | 584.2 | 966.8 | 1,154.8 | ||||||||||||||||||||||
| Selling, general and administrative | 553.8 | 548.0 | 1,135.3 | 1,153.0 | ||||||||||||||||||||||
| Amortization and impairment of acquired intangible assets | 86.9 | 52.9 | 165.2 | 103.1 | ||||||||||||||||||||||
| Collaboration profit sharing/(loss reimbursement) | 62.4 | 56.9 | 128.0 | 114.0 | ||||||||||||||||||||||
| Restructuring charges | 6.6 | 34.4 | 18.1 | 44.0 | ||||||||||||||||||||||
| Gain on sale of PRV | (88.6) | — | (88.6) | — | ||||||||||||||||||||||
| Other (income) expense, net | 85.2 | (121.2) | 178.9 | (51.8) | ||||||||||||||||||||||
| Total cost and expense | 1,766.2 | 1,747.9 | 3,591.9 | 3,772.6 | ||||||||||||||||||||||
| Income before income tax expense and equity in loss of investee, net of tax | 698.7 | 708.1 | 1,163.5 | 1,146.4 | ||||||||||||||||||||||
| Income tax (benefit) expense | 115.1 | 114.8 | 186.5 | 165.5 | ||||||||||||||||||||||
| Net income | 583.6 | 593.3 | 977.0 | 980.9 | ||||||||||||||||||||||
| Net income (loss) attributable to noncontrolling interests, net of tax | — | 1.7 | — | 1.4 | ||||||||||||||||||||||
| Net income attributable to Biogen Inc. | $ | 583.6 | $ | 591.6 | $ | 977.0 | $ | 979.5 | ||||||||||||||||||
| Net income per share: | ||||||||||||||||||||||||||
| Basic earnings per share attributable to Biogen Inc. | $ | 4.01 | $ | 4.09 | $ | 6.72 | $ | 6.78 | ||||||||||||||||||
| Diluted earnings per share attributable to Biogen Inc. | $ | 4.00 | $ | 4.07 | $ | 6.70 | $ | 6.74 | ||||||||||||||||||
| Weighted-average shares used in calculating: | ||||||||||||||||||||||||||
| Basic earnings share attributable to Biogen Inc. | 145.6 | 144.7 | 145.4 | 144.6 | ||||||||||||||||||||||
| Diluted earnings per share attributable to Biogen Inc. | 145.9 | 145.5 | 145.9 | 145.4 | ||||||||||||||||||||||
7
TABLE 2
BIOGEN INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
| As of June 30, 2024 | As of December 31, 2023 | |||||||||||||
| ASSETS | ||||||||||||||
| Cash and cash equivalents | $ | 1,908.9 | $ | 1,049.9 | ||||||||||
| Accounts receivable, net | 1,627.1 | 1,664.1 | ||||||||||||
| Due from anti-CD20 therapeutic programs | 451.1 | 435.9 | ||||||||||||
| Inventory | 2,506.1 | 2,527.4 | ||||||||||||
| Other current assets | 615.3 | 1,182.0 | ||||||||||||
| Total current assets | 7,108.5 | 6,859.3 | ||||||||||||
| Property, plant and equipment, net | 3,249.3 | 3,309.7 | ||||||||||||
| Operating lease assets | 389.4 | 420.0 | ||||||||||||
| Intangible assets, net | 8,232.9 | 8,363.0 | ||||||||||||
| Goodwill | 6,227.4 | 6,219.2 | ||||||||||||
| Deferred tax asset | 915.1 | 928.6 | ||||||||||||
| Investments and other assets | 681.5 | 745.0 | ||||||||||||
| TOTAL ASSETS | $ | 26,804.1 | $ | 26,844.8 | ||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||
| Current portion of term loan | $ | — | $ | 150.0 | ||||||||||
| Taxes payable | 281.6 | 257.4 | ||||||||||||
| Accounts payable | 354.5 | 403.3 | ||||||||||||
| Accrued expenses and other | 2,472.1 | 2,623.6 | ||||||||||||
| Total current liabilities | 3,108.2 | 3,434.3 | ||||||||||||
| Notes payable and term loan | 6,292.0 | 6,788.2 | ||||||||||||
| Deferred tax liability | 590.6 | 641.8 | ||||||||||||
| Long-term operating lease liabilities | 367.5 | 400.0 | ||||||||||||
| Other long-term liabilities | 556.7 | 781.1 | ||||||||||||
| Equity | 15,889.1 | 14,799.4 | ||||||||||||
| TOTAL LIABILITIES AND EQUITY | $ | 26,804.1 | $ | 26,844.8 | ||||||||||
8
TABLE 3
BIOGEN INC. AND SUBSIDIARIES
PRODUCT REVENUE & TOTAL REVENUE
(unaudited, in millions)
Product Revenue
| For the Three Months Ended June 30, | ||||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | |||||||||||||||||||||||||||||||||||||
| United States | Rest of World | Total | United States | Rest of World | Total | |||||||||||||||||||||||||||||||||
| Multiple Sclerosis (MS): | ||||||||||||||||||||||||||||||||||||||
| TECFIDERA | $ | 44.1 | $ | 208.1 | $ | 252.2 | $ | 66.5 | $ | 187.7 | $ | 254.2 | ||||||||||||||||||||||||||
| VUMERITY | 144.2 | 21.6 | 165.8 | 130.3 | 15.9 | 146.2 | ||||||||||||||||||||||||||||||||
| Total Fumarate | 188.3 | 229.7 | 418.0 | 196.8 | 203.6 | 400.4 | ||||||||||||||||||||||||||||||||
| AVONEX | 117.2 | 65.6 | 182.8 | 145.9 | 74.4 | 220.3 | ||||||||||||||||||||||||||||||||
| PLEGRIDY | 28.2 | 39.9 | 68.1 | 34.1 | 48.0 | 82.1 | ||||||||||||||||||||||||||||||||
| Total Interferon | 145.4 | 105.5 | 250.9 | 180.0 | 122.4 | 302.4 | ||||||||||||||||||||||||||||||||
| TYSABRI | 248.7 | 213.5 | 462.2 | 259.9 | 223.2 | 483.1 | ||||||||||||||||||||||||||||||||
| FAMPYRA | — | 18.7 | 18.7 | — | 23.4 | 23.4 | ||||||||||||||||||||||||||||||||
| Subtotal: MS | 582.4 | 567.4 | 1,149.8 | 636.7 | 572.6 | 1,209.3 | ||||||||||||||||||||||||||||||||
| Rare Disease: | ||||||||||||||||||||||||||||||||||||||
| SPINRAZA | 157.3 | 271.8 | 429.1 | 155.8 | 281.3 | 437.1 | ||||||||||||||||||||||||||||||||
SKYCLARYS(1) | 75.6 | 24.4 | 100.0 | — | — | — | ||||||||||||||||||||||||||||||||
QALSODY(2) | 4.6 | 0.4 | 5.0 | 0.9 | — | 0.9 | ||||||||||||||||||||||||||||||||
| Subtotal: Rare Disease | 237.5 | 296.6 | 534.1 | 156.7 | 281.3 | 438.0 | ||||||||||||||||||||||||||||||||
| Biosimilars: | ||||||||||||||||||||||||||||||||||||||
| BENEPALI | — | 117.3 | 117.3 | — | 109.2 | 109.2 | ||||||||||||||||||||||||||||||||
| IMRALDI | — | 53.2 | 53.2 | — | 58.8 | 58.8 | ||||||||||||||||||||||||||||||||
| FLIXABI | — | 13.1 | 13.1 | — | 20.1 | 20.1 | ||||||||||||||||||||||||||||||||
BYOOVIZ(3) | 10.3 | 3.4 | 13.7 | 7.0 | — | 7.0 | ||||||||||||||||||||||||||||||||
TOFIDENCE(4) | 0.8 | — | 0.8 | — | — | — | ||||||||||||||||||||||||||||||||
| Subtotal: Biosimilars | 11.1 | 187.0 | 198.1 | 7.0 | 188.1 | 195.1 | ||||||||||||||||||||||||||||||||
| Other: | ||||||||||||||||||||||||||||||||||||||
ZURZUVAE(5) | 14.9 | — | 14.9 | — | — | — | ||||||||||||||||||||||||||||||||
Other(6) | 0.8 | 1.9 | 2.7 | 0.6 | 2.8 | 3.4 | ||||||||||||||||||||||||||||||||
| Subtotal: Other | 15.7 | 1.9 | 17.6 | 0.6 | 2.8 | 3.4 | ||||||||||||||||||||||||||||||||
| Total product revenue | $ | 846.7 | $ | 1,052.9 | $ | 1,899.6 | $ | 801.0 | $ | 1,044.8 | $ | 1,845.8 | ||||||||||||||||||||||||||
(1) SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.
(2) QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.
(3) BYOOVIZ became commercially available in certain international markets in 2023.
(4) TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.
(5) ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.
(6) Other includes FUMADERM and ADUHELM.
9
| For the Six Months Ended June 30, | ||||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | |||||||||||||||||||||||||||||||||||||
| United States | Rest of World | Total | United States | Rest of World | Total | |||||||||||||||||||||||||||||||||
| Multiple Sclerosis (MS): | ||||||||||||||||||||||||||||||||||||||
| TECFIDERA | $ | 87.8 | $ | 418.7 | $ | 506.5 | $ | 141.2 | $ | 387.5 | $ | 528.7 | ||||||||||||||||||||||||||
| VUMERITY | 250.1 | 43.2 | 293.3 | 223.8 | 30.6 | 254.4 | ||||||||||||||||||||||||||||||||
| Total Fumarate | 337.9 | 461.9 | 799.8 | 365.0 | 418.1 | 783.1 | ||||||||||||||||||||||||||||||||
| AVONEX | 228.4 | 132.9 | 361.3 | 248.5 | 144.2 | 392.7 | ||||||||||||||||||||||||||||||||
| PLEGRIDY | 56.8 | 76.4 | 133.2 | 64.0 | 91.3 | 155.3 | ||||||||||||||||||||||||||||||||
| Total Interferon | 285.2 | 209.3 | 494.5 | 312.5 | 235.5 | 548.0 | ||||||||||||||||||||||||||||||||
| TYSABRI | 462.5 | 431.0 | 893.5 | 505.3 | 450.6 | 955.9 | ||||||||||||||||||||||||||||||||
| FAMPYRA | — | 37.9 | 37.9 | — | 47.5 | 47.5 | ||||||||||||||||||||||||||||||||
| Subtotal: MS | 1,085.6 | 1,140.1 | 2,225.7 | 1,182.8 | 1,151.7 | 2,334.5 | ||||||||||||||||||||||||||||||||
| Rare Disease: | ||||||||||||||||||||||||||||||||||||||
| SPINRAZA | 305.8 | 464.6 | 770.4 | 302.5 | 577.9 | 880.4 | ||||||||||||||||||||||||||||||||
SKYCLARYS(1) | 148.6 | 29.4 | 178.0 | — | — | — | ||||||||||||||||||||||||||||||||
QALSODY(2) | 9.0 | 0.6 | 9.6 | 0.9 | — | 0.9 | ||||||||||||||||||||||||||||||||
| Subtotal: Rare Disease | 463.4 | 494.6 | 958.0 | 303.4 | 577.9 | 881.3 | ||||||||||||||||||||||||||||||||
| 0 | ||||||||||||||||||||||||||||||||||||||
| Biosimilars: | ||||||||||||||||||||||||||||||||||||||
| BENEPALI | — | 236.0 | 236.0 | — | 218.2 | 218.2 | ||||||||||||||||||||||||||||||||
| IMRALDI | — | 108.0 | 108.0 | — | 113.2 | 113.2 | ||||||||||||||||||||||||||||||||
| FLIXABI | — | 30.9 | 30.9 | — | 40.5 | 40.5 | ||||||||||||||||||||||||||||||||
BYOOVIZ(3) | 14.0 | 5.3 | 19.3 | 15.2 | 0.4 | 15.6 | ||||||||||||||||||||||||||||||||
TOFIDENCE(4) | 0.8 | — | 0.8 | — | — | — | ||||||||||||||||||||||||||||||||
| Subtotal: Biosimilars | 14.8 | 380.2 | 395.0 | 15.2 | 372.3 | 387.5 | ||||||||||||||||||||||||||||||||
| Other: | ||||||||||||||||||||||||||||||||||||||
ZURZUVAE(5) | 27.3 | — | 27.3 | — | — | — | ||||||||||||||||||||||||||||||||
Other(6) | 1.7 | 3.8 | 5.5 | 1.0 | 4.8 | 5.8 | ||||||||||||||||||||||||||||||||
| Subtotal: Other | 29.0 | 3.8 | 32.8 | 1.0 | 4.8 | 5.8 | ||||||||||||||||||||||||||||||||
| Total product revenue | $ | 1,592.8 | $ | 2,018.7 | $ | 3,611.5 | $ | 1,502.4 | $ | 2,106.7 | $ | 3,609.1 | ||||||||||||||||||||||||||
(1) SKYCLARYS was obtained as part of our acquisition of Reata in September 2023. SKYCLARYS became commercially available in the U.S. during the second quarter of 2023 and we began recognizing revenue from SKYCLARYS in the U.S. during the fourth quarter of 2023, subsequent to our acquisition. SKYCLARYS was approved and became commercially available in the E.U. during the first quarter of 2024.
(2) QALSODY became commercially available in the U.S. during the second quarter of 2023 and commercially available in the E.U. during the second quarter of 2024.
(3) BYOOVIZ became commercially available in certain international markets in 2023.
(4) TOFIDENCE became commercially available in the U.S. during the second quarter of 2024.
(5) ZURZUVAE became commercially available in the U.S. during the fourth quarter of 2023.
(6) Other includes FUMADERM and ADUHELM.
Total Revenue
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
| Product revenue | $ | 1,899.6 | $ | 1,845.8 | $ | 3,611.5 | $ | 3,609.1 | ||||||||||||||||||
| OCREVUS royalties | 336.3 | 325.5 | 639.0 | 609.1 | ||||||||||||||||||||||
RITUXAN/GAZYVA®/LUNSUMIO™ revenue | 103.4 | 103.6 | 190.5 | 216.1 | ||||||||||||||||||||||
| Other revenues from anti-CD20 programs | 4.8 | 4.3 | 9.0 | 7.7 | ||||||||||||||||||||||
| Contract manufacturing, royalty and other revenue | 120.8 | 176.8 | 305.4 | 477.0 | ||||||||||||||||||||||
| Total revenue | $ | 2,464.9 | $ | 2,456.0 | $ | 4,755.4 | $ | 4,919.0 | ||||||||||||||||||
10
TABLE 4
BIOGEN INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
OPERATING EXPENSE, OTHER (INCOME) EXPENSE, NET, AND INCOME TAX
(unaudited, in millions, except effective tax rate)
We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, such as adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, which is defined as net cash flow from operations less capital expenditures. We believe that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals and form the basis of our management incentive programs. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
| Cost of Sales: | ||||||||||||||||||||||||||
| Total cost of sales, GAAP | $ | 546.0 | $ | 592.7 | $ | 1,088.2 | $ | 1,255.5 | ||||||||||||||||||
| Less: amortization of Reata inventory fair value step-up | 42.3 | — | 84.5 | — | ||||||||||||||||||||||
| Total cost of sales, Non-GAAP | $ | 503.7 | $ | 592.7 | $ | 1,003.7 | $ | 1,255.5 | ||||||||||||||||||
| Research and Development Expense: | ||||||||||||||||||||||||||
| Total research and development expense, GAAP | $ | 513.9 | $ | 584.2 | $ | 966.8 | $ | 1,154.8 | ||||||||||||||||||
| Less: amortization of Reata inventory fair value step-up | 44.8 | — | 44.8 | — | ||||||||||||||||||||||
| Less: restructuring charges and other cost saving initiatives | 5.5 | 0.4 | 13.2 | 0.4 | ||||||||||||||||||||||
| Less: other | — | — | (1.4) | 0.1 | ||||||||||||||||||||||
| Total research and development expense, Non-GAAP | $ | 463.6 | $ | 583.8 | $ | 910.2 | $ | 1,154.3 | ||||||||||||||||||
| Selling, General and Administrative Expense: | ||||||||||||||||||||||||||
| Total selling, general and administrative, GAAP | $ | 553.8 | $ | 548.0 | $ | 1,135.3 | $ | 1,153.0 | ||||||||||||||||||
| Less: acquisition-related transaction and integration costs | 6.0 | — | 10.2 | — | ||||||||||||||||||||||
| Less: restructuring charges and other cost saving initiatives | 3.7 | 11.5 | 7.3 | 11.5 | ||||||||||||||||||||||
| Less: other | 2.6 | 2.7 | 6.9 | 5.1 | ||||||||||||||||||||||
| Total selling, general and administrative, Non-GAAP | $ | 541.5 | $ | 533.8 | $ | 1,110.9 | $ | 1,136.4 | ||||||||||||||||||
| Amortization and Impairment of Acquired Intangible Assets: | ||||||||||||||||||||||||||
| Total amortization and impairment of acquired intangible assets, GAAP | $ | 86.9 | $ | 52.9 | $ | 165.2 | $ | 103.1 | ||||||||||||||||||
| Less: amortization of acquired intangible assets | 76.1 | 44.6 | 144.9 | 87.2 | ||||||||||||||||||||||
| Total amortization and impairment of acquired intangible assets, Non-GAAP | $ | 10.8 | $ | 8.3 | $ | 20.3 | $ | 15.9 | ||||||||||||||||||
| Other (Income) Expense, net: | ||||||||||||||||||||||||||
| Total other (income) expense, net, GAAP | $ | 85.2 | $ | (121.2) | $ | 178.9 | $ | (51.8) | ||||||||||||||||||
| Less: (gain) loss on equity security investments | 30.3 | (106.5) | 61.0 | (29.4) | ||||||||||||||||||||||
| Less: other | 0.3 | — | 0.3 | — | ||||||||||||||||||||||
| Total other (income) expense, net, Non-GAAP | $ | 54.6 | $ | (14.7) | $ | 117.6 | $ | (22.4) | ||||||||||||||||||
| Income Tax (Benefit) Expense: | ||||||||||||||||||||||||||
| Total income tax expense, GAAP | $ | 115.1 | $ | 114.8 | $ | 186.5 | $ | 165.5 | ||||||||||||||||||
| Less: income tax effect related to Non-GAAP reconciling items | (30.9) | 5.9 | (60.8) | (20.4) | ||||||||||||||||||||||
| Total income tax expense, Non-GAAP | $ | 146.0 | $ | 108.9 | $ | 247.3 | $ | 185.9 | ||||||||||||||||||
| Effective Tax Rate: | ||||||||||||||||||||||||||
| Total effective tax rate, GAAP | 16.5 | % | 16.2 | % | 16.0 | % | 14.4 | % | ||||||||||||||||||
| Less: impact of GAAP to Non-GAAP adjustments | 0.6 | 0.5 | 0.1 | (0.3) | ||||||||||||||||||||||
| Total effective tax rate, Non-GAAP | 15.9 | % | 15.7 | % | 15.9 | % | 14.7 | % | ||||||||||||||||||
11
TABLE 4 (continued)
BIOGEN INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
NET INCOME ATTRIBUTABLE TO BIOGEN INC. & DILUTED EPS
(unaudited, in millions, except per share amounts)
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
| Net Income (loss) Attributable to Biogen Inc.: | ||||||||||||||||||||||||||
| Total net income (loss) attributable to Biogen Inc., GAAP | $ | 583.6 | $ | 591.6 | $ | 977.0 | $ | 979.5 | ||||||||||||||||||
| Plus: amortization of Reata inventory fair value step-up | 87.0 | — | 129.3 | — | ||||||||||||||||||||||
| Plus: acquisition-related transaction and integration costs | 6.0 | — | 10.2 | — | ||||||||||||||||||||||
| Plus: amortization of acquired intangible assets | 76.1 | 44.6 | 144.9 | 87.2 | ||||||||||||||||||||||
| Plus: restructuring charges and other cost saving initiatives | 15.9 | 46.3 | 38.6 | 56.0 | ||||||||||||||||||||||
| Plus: (gain) loss on equity security investments | 30.3 | (106.5) | 61.0 | (29.4) | ||||||||||||||||||||||
| Plus: income tax effect related to Non-GAAP reconciling items | (30.9) | 5.9 | (60.8) | (20.4) | ||||||||||||||||||||||
| Plus: other | 2.9 | 2.7 | 5.7 | 5.1 | ||||||||||||||||||||||
| Total net income (loss) attributable to Biogen Inc., Non-GAAP | $ | 770.9 | $ | 584.6 | $ | 1,305.9 | $ | 1,078.0 | ||||||||||||||||||
| Diluted Earnings Per Share: | ||||||||||||||||||||||||||
| Total diluted earnings (loss) per share, GAAP | $ | 4.00 | $ | 4.07 | $ | 6.70 | $ | 6.74 | ||||||||||||||||||
| (Less) Plus: adjustments to GAAP net income attributable to Biogen Inc. (as detailed above) | 1.28 | (0.05) | 2.25 | 0.67 | ||||||||||||||||||||||
| Total diluted earnings per share, Non-GAAP | $ | 5.28 | $ | 4.02 | $ | 8.95 | $ | 7.41 | ||||||||||||||||||
12
TABLE 4 (continued)
BIOGEN INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION: REVENUE CHANGE AT CONSTANT CURRENCY
(unaudited)
Revenue changes at constant currency are presented excluding the impact of changes in foreign currency exchange rates and hedging gains or losses. Foreign currency revenue values are converted into U.S. Dollars using the exchange rates from the end of the previous calendar year.
| Q2 2024 vs. Q2 2023 | YTD 2024 vs. YTD 2023 | |||||||||||||
| Total Revenue: | ||||||||||||||
| Revenue change, as reported | 0.4 | % | (3.3) | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.5) | (0.3) | ||||||||||||
| Revenue change at constant currency | 0.9 | % | (3.0) | % | ||||||||||
| Total Product Revenue: | ||||||||||||||
| Revenue change, as reported | 2.9 | % | 0.1 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.8) | (0.5) | ||||||||||||
| Revenue change at constant currency | 3.7 | % | 0.6 | % | ||||||||||
| Total Core Pharmaceutical Revenue (Product revenue and LEQEMBI): | ||||||||||||||
| Revenue change, as reported | 4.7 | % | 1.6 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.9) | (0.6) | ||||||||||||
| Revenue change at constant currency | 5.6 | % | 2.2 | % | ||||||||||
| Total MS Product Revenue: | ||||||||||||||
| Revenue change, as reported | (4.9) | % | (4.7) | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.3) | (0.3) | ||||||||||||
| Revenue change at constant currency | (4.6) | % | (4.4) | % | ||||||||||
| Total TECIDERA Rest of World Revenue | ||||||||||||||
| Revenue change, as reported | 10.9 | % | 8.1 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (1.3) | (1.0) | ||||||||||||
| Revenue change at constant currency | 12.2 | % | 9.1 | % | ||||||||||
| Total VUMERITY Revenue | ||||||||||||||
| Revenue change, as reported | 13.4 | % | 15.3 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.1) | 0.1 | ||||||||||||
| Revenue change at constant currency | 13.5 | % | 15.2 | % | ||||||||||
| Total Rare Disease Revenue | ||||||||||||||
| Revenue change, as reported | 21.9 | % | 8.7 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (3.0) | (1.8) | ||||||||||||
| Revenue change at constant currency | 24.9 | % | 10.5 | % | ||||||||||
| Total SPINRAZA Revenue | ||||||||||||||
| Revenue change, as reported | (1.8) | % | (12.5) | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (2.3) | (1.3) | ||||||||||||
| Revenue change at constant currency | 0.5 | % | (11.2) | % | ||||||||||
| Total Biosimilars Product Revenue: | ||||||||||||||
| Revenue change, as reported | 1.5 | % | 1.9 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | 0.5 | 0.2 | ||||||||||||
| Revenue change at constant currency | 1.0 | % | 1.7 | % | ||||||||||
13
TABLE 4 (continued)
BIOGEN INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION: REVENUE CHANGE AT CONSTANT CURRENCY (continued)
(unaudited)
| Q2 2024 vs. Q2 2023 | YTD 2024 vs. YTD 2023 | |||||||||||||
| Total Other Product Revenue (FUMADERM, ADUHELM and ZURZUVAE): | ||||||||||||||
| Revenue change, as reported | 431.0 | % | 476.6 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (10.0) | (7.4) | ||||||||||||
| Revenue change at constant currency | 441.0 | % | 484.0 | % | ||||||||||
| Total Revenue from Anti-CD20 Therapeutic Programs Revenue: | ||||||||||||||
| Revenue change, as reported | 2.6 | % | 0.7 | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | 0.1 | 0.1 | ||||||||||||
| Revenue change at constant currency | 2.5 | % | 0.6 | % | ||||||||||
| Total Contract Manufacturing, Royalty and Other Revenue: | ||||||||||||||
| Revenue change, as reported | (31.7) | % | (36.0) | % | ||||||||||
| Less: impact of foreign currency translation and hedging gains / losses | (0.1) | 0.6 | ||||||||||||
| Revenue change at constant currency | (31.6) | % | (36.6) | % | ||||||||||
14
TABLE 4 (continued)
BIOGEN INC. AND SUBSIDIARIES
GAAP TO NON-GAAP RECONCILIATION
FREE CASH FLOW
(unaudited, in millions)
We define free cash flow as net cash provided by (used in) operating activities in the period less capital expenditures made in the period. The following table reconciles net cash provided by (used in) operating activities, a GAAP measure, to free cash flow, a Non-GAAP measure.
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||||||||||||
| Cash Flow: | ||||||||||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 625.8 | $ | 487.0 | $ | 1,179.0 | $ | 942.3 | ||||||||||||||||||
| Net cash provided by (used in) investing activities | 466.5 | (753.5) | 400.5 | (1,706.5) | ||||||||||||||||||||||
| Net cash provided by (used in) financing activities | (245.2) | (9.8) | (684.8) | (53.2) | ||||||||||||||||||||||
| Net increase (decrease) in cash and cash equivalents | $ | 847.1 | $ | (276.3) | $ | 894.7 | $ | (817.4) | ||||||||||||||||||
| Net cash provided by (used in) operating activities | $ | 625.8 | $ | 487.0 | $ | 1,179.0 | $ | 942.3 | ||||||||||||||||||
| Less: Purchases of property, plant and equipment | 33.5 | 71.0 | 79.4 | 137.6 | ||||||||||||||||||||||
| Free cash flow | $ | 592.3 | $ | 416.0 | $ | 1,099.6 | $ | 804.7 | ||||||||||||||||||
15
Use of Non-GAAP Financial Measures
We supplement our GAAP consolidated financial statements and GAAP financial measures with other financial measures, such as adjusted net income, adjusted diluted earnings per share, revenue growth at constant currency, which excludes the impact of changes in foreign exchange rates and hedging gains or losses, and free cash flow, which is defined as net cash flow from operations less capital expenditures. We believe that these and other Non-GAAP financial measures provide additional insight into the ongoing economics of our business and reflect how we manage our business internally, set operational goals and form the basis of our management incentive programs. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Our “Non-GAAP net income attributable to Biogen Inc.” and “Non-GAAP earnings per share - Diluted” financial measures exclude the following items from “GAAP net income attributable to Biogen Inc.” and “GAAP earnings per share - Diluted”:
1. Acquisitions and divestitures
We exclude transaction, integration and certain other costs related to the acquisition and divestiture of businesses and items associated with the initial consolidation or deconsolidation of variable interest entities. These adjustments include, but are not limited to, the amortization and impairment of intangible assets, charges or credits from the fair value remeasurement of our contingent consideration obligations and losses on assets and liabilities held for sale.
2. Restructuring, business transformation and other cost saving initiatives
We exclude costs associated with our execution of certain strategies and initiatives to streamline operations, achieve targeted cost reductions, rationalize manufacturing facilities or refocus research and development activities. These costs may include employee separation costs, retention bonuses, facility closing and exit costs, asset impairment charges or additional depreciation when the expected useful life of certain assets have been shortened due to changes in anticipated usage and other costs or credits that management believes do not have a direct correlation to our ongoing or future business operations.
3. (Gain) loss on equity security investments
We exclude unrealized and realized gains and losses related to our equity security investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations.
4. Other items
We evaluate other items of income and expense on an individual basis and consider both the quantitative and qualitative aspects of the item, including (i) its size and nature, (ii) whether or not it relates to our ongoing business operations and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. We also include an adjustment to reflect the related tax effect of all reconciling items within our reconciliation of our GAAP to Non-GAAP net income attributable to Biogen Inc. and earnings per share - diluted.
16